Evidence map›Paper›PMID 35846514›Full record

ArticleUrology case reports2022

Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report.

Midori Hara, Satoru Kira, Manabu Kamiyama, Tatsuya Ihara, Takeshi Sato, Takahiko Mitsui

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Midori HaraDepartment of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.
Satoru KiraDepartment of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.
Manabu KamiyamaDepartment of Urology, Toranomon Hospital Kajigaya, Tokyo, Japan.
Tatsuya IharaDepartment of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.
Takeshi SatoDepartment of Urology, Fujiyoshida Municipal Hospital, Fujiyoshida-city, Yamanashi, Japan.
Takahiko MitsuiDepartment of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.
University of Yamanashi · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of cisplatin and etoposide for 6 months had a certain effect. However, his cancer progressed, and he took genetic screening exams. It revealed that his tumor mutational burden was high, and pembrolizumab was started. In this report, we suggested several new treatments.

Indexed as

Neuroendocrine prostate cancerPeptide receptor radionuclide therapyTumor mutational burden high

Identifiers

PMID35846514
PMCPMC9284398
OpenAlexW4284888067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.